Table of contents:
Video: Generic Influenza Vaccine Passes Important Test
Generic influenza vaccine passes important test
An experimental universal influenza vaccine has been shown to be safe in a small group trial. The vaccine gave participants antibodies against a broad spectrum of influenza viruses for at least six months.
Photo: CC0 Public Domain /
An experimental universal influenza vaccine has been shown to be safe in a small group trial. The vaccine gave participants antibodies against a broad spectrum of influenza viruses for at least six months. The research report was published by the scientists in the Annals of Internal Medicine.
Currently, the best prevention of seasonal flu is with an annual vaccination. Since the virus mutates frequently, a new vaccine is required every year. The World Health Organization annually reports on which strains it should work against. Unfortunately, these predictions are not always completely accurate. In addition, it can be difficult for manufacturers to quickly produce the desired vaccine.
The new, experimental, FLU-v vaccine is a synthetic vaccine that does not require annual correction and can be effective every year. In the trial, she gave good immunity against influenza A and B viruses to study participants for at least six months. In this study, scientists measured only laboratory parameters of immunity against influenza viruses. Whether vaccination can protect against the disease itself will become known after the next phase of the research.
In the study, scientists compared the effectiveness of one and two doses of the new vaccine. To do this, they divided 175 healthy adults into groups, the participants of which were vaccinated in different modes. Those who received one dose of the new boosted vaccine retained antibodies against influenza viruses for six months.
The vaccine's effectiveness in preventing influenza will be evaluated in the next phase of the study.